Journal
EUROPEAN JOURNAL OF CANCER
Volume 148, Issue -, Pages 202-210Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2021.01.052
Keywords
Osimertinib; Resistance; High-throughput nucleotide sequencing; Genomics; T790M mutation; MET amplification
Categories
Funding
- National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea [1520220]
Ask authors/readers for more resources
After resistance to osimertinib, some tumors undergo transformation while others maintain T790M mutations. Novel mutations, including MET amplification, KRAS mutations, PIK3CA mutations, and RET fusion, are identified in patients with T790M loss.
Introduction: Although osimertinib overcomes the T790M mutation acquired after traditional epidermal growth factor receptor (EGFR) gene tyrosine kinase inhibitor (TKI) treatment, resistance to osimertinib eventually occurs. We explored resistance mechanisms of second-line osimertinib and their clinical implications by comparing next-generation sequencing (NGS) results before and after resistance acquisition. Methods: We enrolled 34 patients with advanced EGFR-mutant adenocarcinoma whose biopsied tumour tissues were subjected to targeted NGS at the time of progression on osimertinib. For comparison, NGS was also performed on archived tumour tissues from each patient excised before osimertinib initiation. Results: The tumours of three patients? were observed to have transformed to small-cell carcinoma and those of two patients to squamous cell carcinoma. Among the remaining 29 patients, T790M mutations were maintained in seven patients (24.1%), including four patients (13.8%) acquiring C797S mutations and one with MET amplification. Among the 22 patients (75.9%) with T790M loss, a variety of novel mutations were identified, including KRAS mutations, PIK3CA mutations, and RET fusion, but MET amplifications (n Z 4, 18.2%) were
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available